Evidence map›Paper›PMID 39960558›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

Most European countries will miss EU targets on antibacterial use by 2030: historical analysis of European and OECD countries, comparison of community and hospital sectors and forecast to 2040.

Lilly Josephine Bindel, Roland Seifert

Abstract readComparative Study
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Lilly Josephine BindelInstitute of Pharmacology, Hannover Medical School, D-30625, Hannover, Germany.
Roland SeifertInstitute of Pharmacology, Hannover Medical School, D-30625, Hannover, Germany. seifert.roland@mh-hannover.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rise of bacterial resistance threatens the treatment of infections and is closely linked to the consumption of antibacterial drugs. The EU's 'One Health' approach aims to address this issue by requiring Member States to reduce consumption by 20% by 2030. This study analyses antibacterial consumption trends in the total care of European and non-European OECD countries, compares the community and hospital sector, uses ARIMA modelling and correlation analysis to provide long-term forecasts, assesses patterns of consumption and evaluates whether current trends are in line with the EU target. Projections to 2040 show increases for Spain (+36.6%; 30.7 DID), Greece (+31.4%; 37.5 DID), Czechia (+29.7%; 19.4 DID), Bulgaria (+28.3%; 33. 7 DID), Malta (+26.5%; 28.8 DID), Denmark (+25.7%; 19.8 DID), Croatia (+17.4%; 24.9 DID), Italy (+13.7%; 26.3 DID), Germany (+7.6%; 12.6 DID), Australia (+12.4%, 18.2 DID), Canada (+8.0%, 14.8 DID), Chile (+90.1%, 66.7 DID), Costa Rica (+0.4%, 19.7 DID), Japan (+22.7%, 12.8 DID) and Korea (+24.3%, 31.9 DID). Declines are forecast for Belgium (-0.5%; 20.5 DID), Romania (-0.6%; 27.2 DID), Cyprus (-1.0%; 33.2 DID), Luxembourg (-2.2%; 19.8 DID), Norway (-3.4%; 15.1 DID), Latvia (-5.5%; 14.1 DID), Lithuania (-6.4%; 17.5 DID), the Netherlands (-8.4%; 8. 8 DID), Portugal (-10.6%; 16.1 DID), Estonia (-12.1%; 11.2 DID), Slovakia (-16.1%; 16.8 DID), France (-17.7%; 19.8 DID), Hungary (-20.4%; 11.3 DID), Slovenia (-21.9%; 10.5 DID), Finland (-24.8%; 9.7 DID), Iceland (-24.9%; 13.9 DID), Sweden (-30.4%; 7.0 DID) and Israel (-70.7%, 4.7 DID). A significant positive correlation was found between current versus projected consumption levels and changes, highlighting stable prescribing patterns in many countries. Northern and Central Europe maintain low levels of consumption with decreasing trends, whereas Latin America, Eastern and Southern Europe show higher levels with projected increases. Western Europe and Asia shows a mixed pattern, with varying trends of increase and decrease. Alarmingly, only Sweden is projected to meet the 20% reduction target by 2030. Even in the best-case scenario, only a proportion of European countries are projected to meet the target, including Austria, Belgium, Croatia, Cyprus, Finland, France, Greece, Hungary, Italy, Iceland, Lithuania, Luxembourg, Latvia, Portugal, Slovenia, Slovakia and Spain, while 11 countries show no potential for a successful reduction. The reliability of the projections is considered good to moderate. Divergent trends between the community and hospital sectors further complicate the assessment of progress and underline the need for targeted interventions. Current trends suggest that the EU targets are unlikely to be met, highlighting the urgent need to strengthen stewardship programmes. Further research is needed to address other objectives of the 'One Health' approach, including the use of classes of antibacterial drugs and the development of bacterial resistance.

Indexed as

Anti-Bacterial AgentsDrug UtilizationDrug Resistance, BacterialEuropeEuropean UnionForecastingHospitalsHumansOrganisation for Economic Co-Operation and DevelopmentAnti-Bacterial AgentsAMCAMRAntibacterial drugAntibioticAntibiotic prescriptionAntibiotic StewardshipAntimicrobial consumptionARIMAECDCEUEuropeForecastIrrational prescribing behaviourOECDOne HealthRational prescribing behaviourSurveillance

Identifiers

PMID39960558
PMCPMC12350445

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.